A Study of T-DXd in Patients With Selected HER2-overexpressing Tumors
Conditions: Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) Interventions: Drug: Trastuzumab deruxtecan Sponsors: AstraZeneca; Daiichi Sankyo Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Conditions: Cancers Harboring HER2 Alterations Interventions: Drug: IAM1363; Drug: Trastuzumab Sponsors: Iambic Therapeutics, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Conditions: Gastric Cancer; HER2-positive Gastric Cancer Interventions: Drug: Experimental; Drug: Control Sponsors: Gruppo Oncologico del Nord-Ovest Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
Conditions: Non Small Cell Lung Cancer Interventions: Drug: Trastuzumab deruxtecan Sponsors: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
Conditions: Breast Cancer Interventions: Drug: Trastuzumab deruxtecan (T-DXd) with pyrotinib Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Conditions: Metastatic Colorectal Cancer; Metastatic Gastroesophageal Adenocarcinoma; DPD Deficiency Interventions: Drug: Lonsurf; Drug: Oxaliplatin; Drug: Panitumumab; Drug: Bevacizumab; Drug: Trastuzumab; Drug: Nivolumab Sponsors: UNICANCER; Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Conditions: Advanced Cancer; Breast Cancer Interventions: Drug: OKI-219; Drug: Fulvestrant; Drug: Trastuzumab Sponsors: OnKure, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
Conditions: Breast Cancer Interventions: Drug: Trastuzumab deruxtecan Sponsors: Hospital Israelita Albert Einstein; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Conditions: HER2-positive Breast Cancer; Advanced Breast Cancer Interventions: Drug: Pyrotinib; Drug: Trastuzumab; Drug: Taxanes; Drug: Capecitabine Sponsors: Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Conditions: Cardiotoxicity Induced by Drug Therapy for Breast Cancer Interventions: Drug: Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis) Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Conditions: HER2-positive Breast Cancer; HER2-low Breast Cancer; Breast Cancer; Advanced Cancer Interventions: Drug: Trastuzumab deruxtecan Sponsors: Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (China), a Daiichi Sankyo Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Conditions: Breast Cancer, Familial Male; Radiotherapy; Complications; Chemotherapeutic Toxicity; Immune Checkpoint Inhibitor; CDK4/6 Inhibitor; Trastuzumab; Pertuzumab; PARP Inhibitor Interventions: Radiation: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients) Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy
Conditions: Breast Cancer Interventions: Other: High Intensity Interval Training (HIIT); Drug: neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab) Sponsors: The Greater Poland Cancer Centre Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
Conditions: Biliary Tract Cancer; HER2 Gene Mutation Interventions: Drug: SOC plus trastuzumab and pembrolizumab Sponsors: Institut f ür Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel; MSD Sharp& Dohme GmbH, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 21, 2023 Category: Research Source Type: clinical trials
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer Interventions: Drug: Trastuzumab deruxtecan; Drug: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection; Drug: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection Sponsors: MedSIR; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials
